NEW YORK (GenomeWeb) – Oxford BioDynamics said today that its subsidiary, Oxford BioDynamics Pte, has signed an exclusive license agreement with Nova Satra Diagnostics Asia (NSDA) under which NSDA will be able to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia using Oxford's EpiSwitch technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.